Expand INMB Menu
INMB MENU

INMB Latest Press Releases

-- September 14, 2026 --

INmune Bio Appoints Sanofi Rare-Disease Executive and Biopharma Business Development Leader to Board Globe Newswire 7:00 AM

-- September 9, 2026 --

INmune Bio to Present at the H.C. Wainwright Global Investment Conference Globe Newswire 8:00 AM

-- August 26, 2026 --

INmune Bio Advances Ebstrocel Toward European Marketing Authorization with EMA Regulatory Filings Globe Newswire 7:00 AM

-- August 6, 2026 --

INmune Bio Inc. Announces Second Quarter 2026 Results and Highlights Regulatory, Manufacturing and Clinical Progress Globe Newswire 4:00 PM

-- July 31, 2026 --

INmune Bio Receives R&D Rebates of Approximately $4.6 Million Globe Newswire 7:00 AM
INmune Bio Inc. to Report Second Quarter 2026 Financial Results and Provide Corporate Update on Thursday, August 6th Globe Newswire 7:00 AM

-- July 30, 2026 --

INmune Bio Establishes Scientific Advisory Board to Support Late-Stage Development and Expansion of CORDStrom Platform Globe Newswire 7:00 AM

-- July 20, 2026 --

INmune Bio Completes Commercial Manufacturing Milestone Supporting Planned Global Registration Filings for CORDStrom Platform Globe Newswire 7:00 AM

-- July 15, 2026 --

INmune Bio's XPro1595 Prevents Brain-Injury-Induced Alzheimer's Pathology, Memory Loss, and Pain in New Peer-Reviewed Preclinical Study Globe Newswire 7:00 AM

-- July 9, 2026 --

INmune Bio to Present Positive Phase 2 Imaging Data for XPro in Early Alzheimer's Disease at AAIC Globe Newswire 7:00 AM

-- July 1, 2026 --

INmune Bio Advances CORDStrom Platform Patent Application in the U.S. Following Favorable International Written Opinion Globe Newswire 7:00 AM

-- June 25, 2026 --

INmune Bio Inc. Achieves MHRA Approval of PIP for CORDStrom Globe Newswire 7:00 AM

-- June 23, 2026 --

INmune Bio Receives MHRA Written Alignment Supporting Planned 2026 UK Conditional Marketing Authorization Application for CORDStrom in RDEB Globe Newswire 8:00 AM

-- June 2, 2026 --

INmune Bio Reports Statistically Significant Treatment Effect on Advanced White Matter MRI Biomarker in Phase 2 MINDFuL Alzheimer's Trial Globe Newswire 8:00 AM

-- May 15, 2026 --

INmune Bio Publishes Phase 2 MINDFuL Trial Results in NPJ Dementia, Advancing the XPro Platform Globe Newswire 8:00 AM

-- May 14, 2026 --

INmune Bio Receives FDA Fast Track Designation for XPro1595 in Early Alzheimer's Disease Globe Newswire 8:00 AM

-- May 13, 2026 --

INmune Bio Named Founding Member of the American Biotech Innovation Alliance (ABIA) as U.S. Biotech Sector Navigates Strategic Inflection Point Globe Newswire 8:00 AM

-- May 7, 2026 --

INmune Bio Inc. Announces First Quarter 2026 Results and Provides Business Update Globe Newswire 4:00 PM

-- May 5, 2026 --

INmune Bio and Anthony Nolan Announce Strategic Expansion of CORDStrom MSC Platform Collaboration to Target RDEB, Oncology, and Inflammatory Diseases Globe Newswire 4:00 PM
Biotech Leaders Launch National Alliance to Define the Future of American Innovation Business Wire 7:00 AM

-- April 30, 2026 --

INmune Bio Inc. to Report First Quarter 2026 Financial Results and Provide Corporate Update on Thursday, May 7th Globe Newswire 8:00 AM

-- April 16, 2026 --

INmune Bio Inc. Announces New Preclinical Data at AACR 2026 Demonstrating INB03 (XPro1595) Overcomes Resistance and Reduces Metastases in HER2-Positive Breast Cancer Models Globe Newswire 8:00 AM
Market Data Delayed 15 Minutes